XBIO xeneticbio.com Final Profit

Corporate emblem and logo of xeneticbio.com (XBIO)

Xenetic Biosciences (XBIO) develops cellular platforms to combat oncology, focusing on the biotech sector. The company's profit reflects its current stage of development, where the -0.00 mark serves as a key metric. Growth potential is based on patent licensing by pharma behemoths, although the lack of commercial sales and reliance on equity issuance define the company's current financial profile.

XBIO (Xenetic Bio) Net Profit history from 07/04/2022 to 11/01/2026

Analytical breakdowns and data insights for company xeneticbio.com (XBIO)

- stock value and consensus price forecast:
Market Price Xenetic Biosciences, Inc.|XBIO - Price Target Chart
- market capitalization data:
Market Value Xenetic Biosciences, Inc.|XBIO - Real Price to Acquire Entire Company
- business book valuation details:
Accounting Value of a Share Xenetic Biosciences|XBIO - Book Capitalization|Market Cap to Net Assets Ratio xeneticbio.com|XBIO - Cumulative Company Assets
- debt and solvency information:
Total Debt to Capital Xenetic Biosciences|XBIO - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Xenetic Biosciences, Inc.|XBIO - Company Aggregate Debts|Debts to Book Value Xenetic Biosciences, Inc.|XBIO - Company Long-Term Liabilities|Company Short-Term Indebtedness Xenetic Biosciences|Immediate Liquidity xeneticbio.com
- net income and valuation multiples indicators:
XBIO - Company Net Income
Fundamental valuation:XBIO Xenetic Bio
Manufactured product of Xenetic Biosciences Inc.

Investors should utilize net margin analysis to identify hidden costs, assessing the real margin of safety for Xenetic Biosciences (XBIO) through its bottom-line profit dynamics. Since demand for Xenetic Biosciences (XBIO) oncology vaccines is independent of macroeconomic factors, this indicator reflects the business's operational resilience, where a stable earnings curve confirms the company's reliability regardless of inflationary shocks.

Key competitors

Company Net Income BeiGene Oncology (ONC)|Company Net Income Halozyme Therapeutics|RVMD: Final Profit|Net Income AAPG (Ascentage Pharma)|CGON (CG Oncology Inc) - Final Profit|Net Profit URGN (UroGen)|BCAX - Net Income|PSNL: Net Income|ERAS - Net Profit|Delcath Systems (DCTH) - Company Net Income|Y-mAbs Therapeutics Inc - Final Profit|AURA (Aura Bio) - Net Profit|Company Net Income Candel CADL|Net Income ARAY (Accuray Incorporated)|sellaslifesciences.com - Company Profit|Net Profit ACTU (Actuate Therapeutics)|Citius Oncology Inc. (CTOR) - Company Net Income|HURA - Company Net Income|TARA (Protara Tx) - Company Profit|FATE: Net Profit|Company Net Income Aadi Bioscience (WHWK)|Net Income TCRX|CSBR (Champions Oncology Corp) - Profit After Payment of Taxes|Net Profit XBIT|Net Financial Result cel-sci.com|Net Profit OSTX (OS Therapies Incorporated)|RADX - Net Income|ARTV: Net Income|Final Profit ANL (Adlai Nortye Ltd.)|VERU: Net Profit|TPST (Tempest Therapeutics Corp) - Company Net Income|XLO (Xilio Therapeutics Inc) - Net Profit|Enochian BioSciences (RENB) - Net Financial Result|Company Net Income Mural Oncology plc (MURA)|KAPA - Company Net Income|Company Net Income OnKure Therapeutics OKUR|Net Financial Result CytoMed Therapeutics Ltd (GDTC)|Curis Corp - Net Profit|Apollomics, Inc. (APLM) - Net Income|THAR: Net Profit|ADVB - Net Financial Result|GNPX (Genprex, Inc) - Net Profit|Company Net Income Calidi Bio CLDI|Company Net Income Sunshine Biopharma (SBFM)|salariuspharma.com - Company Profit|Net Profit PPBT (Purple Biotech Ltd.)|AONC - Net Income|BeOne Medicines - Net Profit|Company Net Income Checkpoint Therapeutics Inc|Elevation Oncology, Inc. (ELEV) - Company Net Income|ICAD - Net Financial Result|Net Income IKNA|Company Profit NTBL (Notable Labs Ltd)|Net Profit VIRX|Company Net Income MOR (MorphoSys Corporation)|Net Profit NAYA (NAYA Biosciences)|Net Financial Result ascentage.com (AAPGV)